Scott Williams - Concepedia

Author

Scott Williams

Also Known As

Andrew Weickhardt, Elizabeth Christie, Pamela Russell, S Williams, S. Williams, S.G. Williams, Scott G Williams, Scott G. Williams, Scott Garrick Williams, Scott Williams

274

Publications

16.5K

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Monash University The University of Sydney Eastern Health

About

Scott Williams is an author at Peter MacCallum Cancer Centre specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	57	8.7K
2	Health Sciences	15	17	2.6K
3	Engineering	3	3	123
4	Natural Sciences	2	2	46
5	Public Health	1	1	17

Scott Williams

109

Publications

13.1K

Citations

H-Index

Page 1

	Year	Citations
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, The Lancet UrologySurgical OncologyHigh-risk Prostate CancerGenitourinary CancerOncologic Imaging	2020	1.8K
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Ian D. Davis, Andrew Martin, Martin R. Stockler, New England Journal of Medicine	2019	1.5K
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Michael S. Hofman, John Violet, Rodney J. Hicks, The Lancet Oncology	2018	1.1K
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Michael S. Hofman, Louise Emmett, Shahneen Sandhu, The Lancet UrologyOncologyGenitourinary CancerMedicineClinical Trials	2021	1K
Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study John Yaxley, Geoffrey D. Coughlin, Suzanne K. Chambers, The Lancet LaparoscopyUrologySurgical OncologyControlled Phase 3Medicine	2016	678
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes John Violet, Price Jackson, Justin Ferdinandus, Journal of Nuclear Medicine	2018	454
Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study Geoffrey D. Coughlin, John Yaxley, Suzanne K. Chambers, The Lancet Oncology 24-Month OutcomesLaparoscopyUrologySurgical OncologyMedicine	2018	444
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial Andrew Kneebone, Carol Fraser‐Browne, Gillian Duchesne, The Lancet Oncology Surgical OncologyUrologyRadiation TherapyMedicineRadical Prostatectomy	2020	349
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer John Violet, Shahneen Sandhu, Amir Iravani, Journal of Nuclear Medicine	2019	269
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial James P Buteau, Andrew Martin, Louise Emmett, The Lancet Oncology Biomarker (Medicine)Prognostic BiomarkersUrologyOncologyBiomarker Analysis	2022	239

Page 1